巴瑞替尼-话题@MedSci

#巴瑞替尼#

13篇内容 | 3855人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2235876, encodeId=170622358e68a, content=<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=斑秃患者有救了！2 大药物已上市，80%的患者实现毛发再生！一文盘点当下热门 Jak抑制！, objectType=article, longId=850453, objectId=592b8504537b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021916/1631760750127_5552845.jpg, objectUrl=/article/show_article.do?id=592b8504537b, replyNumber=0, likeNumber=22, createdTime=2024-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=592b8504537b, moduleTitle=斑秃患者有救了！2 大药物已上市，80%的患者实现毛发再生！一文盘点当下热门 Jak抑制！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=592b8504537b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2235875, encodeId=5ca722358e566, content=<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=80% 的毛发实现再生！斑秃患者有救了！, objectType=article, longId=850449, objectId=323385044913, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241108/1731045521971_5134304.png, objectUrl=/article/show_article.do?id=323385044913, replyNumber=0, likeNumber=21, createdTime=2024-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=323385044913, moduleTitle=80% 的毛发实现再生！斑秃患者有救了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=323385044913)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2235842, encodeId=ef3922358427d, content=<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=从真实世界研究看巴瑞替尼治疗中国重度斑秃患者的疗效 | 2024 ADC, objectType=article, longId=850341, objectId=c4bb8503412c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241108/1731032066756_5134304.png, objectUrl=/article/show_article.do?id=c4bb8503412c, replyNumber=0, likeNumber=20, createdTime=2024-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c4bb8503412c, moduleTitle=从真实世界研究看巴瑞替尼治疗中国重度斑秃患者的疗效 | 2024 ADC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4bb8503412c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2235841, encodeId=6d03223584135, content=<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=斑秃的病理机制以及难治性斑秃的治疗选择, objectType=article, longId=850339, objectId=917385033921, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241108/1731031492545_5134304.png, objectUrl=/article/show_article.do?id=917385033921, replyNumber=0, likeNumber=21, createdTime=2024-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=917385033921, moduleTitle=斑秃的病理机制以及难治性斑秃的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917385033921)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230323, encodeId=2e482230323b3, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a> <a href='/topic/show?id=d0cc111944b6' target=_blank style='color:#2F92EE;'>#类风湿关节炎（RA）#</a> <a href='/topic/show?id=970b120039c9' target=_blank style='color:#2F92EE;'>#三价铬#</a>, objectTitle=Inflammopharmacology：三价铬与巴瑞替尼治疗类风湿关节炎的临床疗效与安全性比较, objectType=article, longId=846490, objectId=016384649073, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240729/1722218606037_8538692.png, objectUrl=/article/show_article.do?id=016384649073, replyNumber=0, likeNumber=43, createdTime=2024-10-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=016384649073, moduleTitle=Inflammopharmacology：三价铬与巴瑞替尼治疗类风湿关节炎的临床疗效与安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=016384649073)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181193, encodeId=8ff1218119356, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a> <a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a> <a href='/topic/show?id=490795953ed' target=_blank style='color:#2F92EE;'>#重症新冠肺炎#</a>, objectTitle=Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应, objectType=article, longId=808241, objectId=cba8808241a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668025373131_4754896.webp, objectUrl=/article/show_article.do?id=cba8808241a1, replyNumber=0, likeNumber=126, createdTime=2024-01-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cba8808241a1, moduleTitle=Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba8808241a1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176904, encodeId=0e6d21e69041e, content=<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a> <a href='/topic/show?id=c785e225813' target=_blank style='color:#2F92EE;'>#盐#</a> <a href='/topic/show?id=d8e319241a4' target=_blank style='color:#2F92EE;'>#β细胞功能#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a> <a href='/topic/show?id=05b11089e63a' target=_blank style='color:#2F92EE;'>#阿米卡星#</a> <a href='/topic/show?id=30fc10822031' target=_blank style='color:#2F92EE;'>#四大顶刊#</a> <a href='/topic/show?id=4f3c1089061d' target=_blank style='color:#2F92EE;'>#化石燃料#</a>, objectTitle=‘四大顶刊’一周研究导读：巴瑞替尼对β细胞功能的保护；阿米卡星可显著降低呼吸机相关肺炎风险；低钠饮食可显著降压；减少化石燃料可拯救数百万人生命, objectType=article, longId=806772, objectId=cff3806e729c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668022044810_4754896.jpeg, objectUrl=/article/show_article.do?id=cff3806e729c, replyNumber=0, likeNumber=104, createdTime=2023-12-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cff3806e729c, moduleTitle=‘四大顶刊’一周研究导读：巴瑞替尼对β细胞功能的保护；阿米卡星可显著降低呼吸机相关肺炎风险；低钠饮食可显著降压；减少化石燃料可拯救数百万人生命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff3806e729c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176314, encodeId=b1d521e63141c, content=<a href='/topic/show?id=c6fc6e299' target=_blank style='color:#2F92EE;'>#1型糖尿病#</a> <a href='/topic/show?id=1a688385505' target=_blank style='color:#2F92EE;'>#胰岛β细胞#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=NEJM：巴瑞替尼与新发1型糖尿病患者的胰岛β细胞功能, objectType=article, longId=806325, objectId=ab928063258b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016434455_4754896.png, objectUrl=/article/show_article.do?id=ab928063258b, replyNumber=0, likeNumber=135, createdTime=2023-12-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab928063258b, moduleTitle=NEJM：巴瑞替尼与新发1型糖尿病患者的胰岛β细胞功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab928063258b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174226, encodeId=659221e42260e, content=<a href='/topic/show?id=c6fc6e299' target=_blank style='color:#2F92EE;'>#1型糖尿病#</a> <a href='/topic/show?id=253c83869a5' target=_blank style='color:#2F92EE;'>#胰岛素依赖#</a> <a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>, objectTitle=“告别”胰岛素依赖！NEJM：这种药或有望成为“首个”1型糖尿病改善药物, objectType=article, longId=804497, objectId=0f2280449e35, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221115/1668549991895_4754896.webp, objectUrl=/article/show_article.do?id=0f2280449e35, replyNumber=0, likeNumber=102, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0f2280449e35, moduleTitle=“告别”胰岛素依赖！NEJM：这种药或有望成为“首个”1型糖尿病改善药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2280449e35)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2164869, encodeId=cfe1216486938, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a> , objectTitle=2023 NICE 介入程序指南：巴瑞替尼治疗重度斑秃 [TA926], objectType=guider, longId=26766, objectId=bcee21c003a12e69, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=bcee21c003a12e69, replyNumber=0, likeNumber=163, createdTime=2023-10-25, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bcee21c003a12e69, moduleTitle=2023 NICE 介入程序指南：巴瑞替尼治疗重度斑秃 [TA926], moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=bcee21c003a12e69)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2092798, encodeId=81082092e98f3, content=美国食品和药物管理局（<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>）批准了礼来和 Incyte 公司开发的用于治疗成人<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a>的口服药物 <a href='/topic/show?id=7fa8104913ea' target=_blank style='color:#2F92EE;'>#JAK 抑制剂#</a><a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>（<a href='/topic/show?id=e55a3203bc' target=_blank style='color:#2F92EE;'>#baricitinib#</a>）。这也是 FDA 首次批准治疗斑秃的全身性系统疗法（而非身体的特定部位）。, objectTitle=NEJM：可恢复80%头发生长，FDA批准首款口服抗脱发新药上市, objectType=article, longId=729601, objectId=94b7e29601db, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220615/1655261533816_5295905.jpg, objectUrl=/article/show_article.do?id=94b7e29601db, replyNumber=1, likeNumber=155, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b7e29601db, moduleTitle=NEJM：可恢复80%头发生长，FDA批准首款口服抗脱发新药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b7e29601db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242634, encodeId=80a612426348a, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>治疗<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>, objectTitle=Ann Rheum Dis：放心用！研究证实巴利替尼治疗类风湿性关节炎的长期安全性, objectType=article, longId=724210, objectId=c75be24210d4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/119.jpg, objectUrl=/article/show_article.do?id=c75be24210d4, replyNumber=0, likeNumber=152, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75be24210d4, moduleTitle=Ann Rheum Dis：放心用！研究证实巴利替尼治疗类风湿性关节炎的长期安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c75be24210d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242633, encodeId=4a471242633bd, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>在治疗进展性<a href='/topic/show?id=656be170520' target=_blank style='color:#2F92EE;'>#白癜风#</a>, objectTitle=Dose Response ：巴瑞西尼在治疗进展性白癜风的体内外实验中均有明显疗效, objectType=article, longId=732832, objectId=a3ade328322a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220720/1658281972502_5552845.jpg, objectUrl=/article/show_article.do?id=a3ade328322a, replyNumber=0, likeNumber=151, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3ade328322a, moduleTitle=Dose Response ：巴瑞西尼在治疗进展性白癜风的体内外实验中均有明显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3ade328322a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242632, encodeId=a5671242632fd, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>在活动性<a href='/topic/show?id=257ae692755' target=_blank style='color:#2F92EE;'>#系统性红斑狼疮#</a>, objectTitle=ARD：巴瑞替尼在活动性系统性红斑狼疮患者中的作用机制及生物标志物和关键免疫通路的鉴定, objectType=article, longId=728125, objectId=d19fe2812566, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220530/1653874594463_5552845.jpg, objectUrl=/article/show_article.do?id=d19fe2812566, replyNumber=0, likeNumber=173, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19fe2812566, moduleTitle=ARD：巴瑞替尼在活动性系统性红斑狼疮患者中的作用机制及生物标志物和关键免疫通路的鉴定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19fe2812566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242631, encodeId=4c071242631ee, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>治疗复发性<a href='/topic/show?id=ea86482116d' target=_blank style='color:#2F92EE;'>#巨细胞动脉炎#</a>, objectTitle=ARD：巴瑞替尼治疗复发性巨细胞动脉炎：一项52周的前瞻性开放标签试验研究, objectType=article, longId=731018, objectId=bfa1e31018fc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220701/1656666133079_5552845.jpg, objectUrl=/article/show_article.do?id=bfa1e31018fc, replyNumber=0, likeNumber=131, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfa1e31018fc, moduleTitle=ARD：巴瑞替尼治疗复发性巨细胞动脉炎：一项52周的前瞻性开放标签试验研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfa1e31018fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242630, encodeId=564a12426303d, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>可快速改善快速中重度<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>患者的皮肤疼痛程度, objectTitle= J Cutan Med Surg：巴瑞克替尼可快速改善快速中重度特应性皮炎患者的皮肤疼痛程度, objectType=article, longId=736646, objectId=2330e36646c6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220824/1661306728377_5552845.jpg, objectUrl=/article/show_article.do?id=2330e36646c6, replyNumber=0, likeNumber=119, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2330e36646c6, moduleTitle= J Cutan Med Surg：巴瑞克替尼可快速改善快速中重度特应性皮炎患者的皮肤疼痛程度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2330e36646c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242629, encodeId=922b1242629bb, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>（JAK抑制剂）治疗活动性<a href='/topic/show?id=c04a48e438b' target=_blank style='color:#2F92EE;'>#干燥综合征#</a>, objectTitle=ARD：巴瑞替尼（JAK抑制剂）治疗活动性干燥综合征的初步研究, objectType=article, longId=723469, objectId=e50ae23469ec, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220406/1649225548758_5552845.jpg, objectUrl=/article/show_article.do?id=e50ae23469ec, replyNumber=0, likeNumber=158, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e50ae23469ec, moduleTitle=ARD：巴瑞替尼（JAK抑制剂）治疗活动性干燥综合征的初步研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e50ae23469ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242628, encodeId=36d812426281e, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>治疗<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a>, objectTitle=NEJM：巴瑞替尼治疗斑秃，40%患者头发覆盖能达到80%！（BRAVE-AA研究）, objectType=article, longId=301780, objectId=b832301e80f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220326/97c31d6946494863a6f95ff128a9aaa5.jpg, objectUrl=/article/show_article.do?id=b832301e80f4, replyNumber=0, likeNumber=187, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b832301e80f4, moduleTitle=NEJM：巴瑞替尼治疗斑秃，40%患者头发覆盖能达到80%！（BRAVE-AA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b832301e80f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1242627, encodeId=617a124262e62, content=<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>、<a href='/topic/show?id=d15b546e9f7' target=_blank style='color:#2F92EE;'>#托法替布#</a>与<a href='/topic/show?id=87293296e3' target=_blank style='color:#2F92EE;'>#bDMARDs#</a>治疗<a href='/topic/show?id=6d00e616523' target=_blank style='color:#2F92EE;'>#类风湿关节炎#</a>的疗效比较, objectTitle=Rheumatology：巴瑞替尼、托法替布与bDMARDS治疗类风湿关节炎的疗效比较, objectType=article, longId=299909, objectId=e2b12999097b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202232/1646188506704_5552845.jpg, objectUrl=/article/show_article.do?id=e2b12999097b, replyNumber=0, likeNumber=167, createdTime=2022-09-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2b12999097b, moduleTitle=Rheumatology：巴瑞替尼、托法替布与bDMARDS治疗类风湿关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2b12999097b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1200143, encodeId=f424120014317, content=应该是<a href='/topic/show?id=d15b546e9f7' target=_blank style='color:#2F92EE;'>#托法替布#</a>与<a href='/topic/show?id=00664830602' target=_blank style='color:#2F92EE;'>#巴瑞替尼#</a>在<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>中的比较, objectTitle=Ann Rheum Dis：托法替尼与巴瑞替尼治疗类风湿性关节炎的疗效比较, objectType=article, longId=216302, objectId=bb7f21630220, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021825/1629862199776_1613704.jpg, objectUrl=/article/show_article.do?id=bb7f21630220, replyNumber=0, likeNumber=185, createdTime=2022-03-07, rootId=0, userName=医者仁者, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb7f21630220, moduleTitle=Ann Rheum Dis：托法替尼与巴瑞替尼治疗类风湿性关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb7f21630220)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

巴瑞替尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#斑秃# #巴瑞替尼#

斑秃患者有救了！2 大药物已上市，80%的患者实现毛发再生！一文盘点当下热门 Jak抑制！

2024-11-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#斑秃# #巴瑞替尼#

80% 的毛发实现再生！斑秃患者有救了！

2024-11-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#斑秃# #巴瑞替尼#

从真实世界研究看巴瑞替尼治疗中国重度斑秃患者的疗效 | 2024 ADC

2024-11-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#斑秃# #巴瑞替尼#

斑秃的病理机制以及难治性斑秃的治疗选择

2024-11-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#巴瑞替尼# #类风湿关节炎（RA）# #三价铬#

Inflammopharmacology：三价铬与巴瑞替尼治疗类风湿关节炎的临床疗效与安全性比较

2024-10-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#巴瑞替尼# #新冠肺炎# #重症新冠肺炎#

Critical Care Medicine：巴瑞替尼与c治疗重症新冠肺炎的疗效与不良反应

2024-01-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#高血压# #盐# #β细胞功能# #巴瑞替尼# #阿米卡星# #四大顶刊# #化石燃料#

‘四大顶刊’一周研究导读：巴瑞替尼对β细胞功能的保护；阿米卡星可显著降低呼吸机相关肺炎风险；低钠饮食可显著降压；减少化石燃料可拯救数百万人生命

2023-12-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#1型糖尿病# #胰岛β细胞# #巴瑞替尼#

NEJM：巴瑞替尼与新发1型糖尿病患者的胰岛β细胞功能

2023-12-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#1型糖尿病# #胰岛素依赖# #巴瑞替尼#

“告别”胰岛素依赖！NEJM：这种药或有望成为“首个”1型糖尿病改善药物

2023-12-11发表于上海

(审核中...)

前往app查看评论内容

#巴瑞替尼#

2023 NICE 介入程序指南：巴瑞替尼治疗重度斑秃 [TA926]

2023-10-25发表于上海

lifestar (审核中...)